Healius reports FY26 results matching guidance
- Healius (ASX:HLS) reported a group underlying revenue of $1.37 billion alongside an underlying EBIT of $30.2 million for the 2026 financial year.
- Following the full-year operational update, the market recorded activity for the healthcare provider on the local exchange.
- The business stated that ongoing strategy focuses on revenue quality, network optimisation, and technology-enabled productivity.
Healius (ASX:HLS) reported a group underlying revenue of $1.37 billion and an underlying EBIT of $30.2 for the financial year ended June 30.
The group reported a reported net loss after tax of $415.6 million, including discontinued operations and impairment charges of $332.0 million.
The healthcare provider navigated ongoing sector volume and labour cost pressures through disciplined cost management and improved second-half pathology margins.
The company stated that the period marked operational improvement driven by stronger underlying earnings and fee growth across pathology and Agilex Biolabs.
The group's underlying revenue improved 2.1% over the prior comparative period, while Agilex revenue expanded 14.1% to reach $43.6 million.
Pathology revenues grew by 1.8%, despite a 1.3% reduction in volumes compared to the prior year.
Following the announcement, the Healius share price was down at $0.43.
Healius expects FY27 EBIT to be in line with consensus EBIT of $39.7 million.
Healius maintained its core focus on restoring sustainable margin and cash flow performance through network optimisation and technology-enabled productivity.
